Identification of T-Cell Receptors (TCR)
Background:
The NIH National Cancer
Institute's Surgery Branch seeks a research partner to further
develop, evaluate, or commercialize adoptive immunotherapy
therapeutics under a Collaboration Agreement or a Cooperative
Research and Development Agreement (CRADA).
Technology:
Adoptive immunotherapy
circumvents a major limitation of the current chemotherapy-based
therapeutics, i.e., cytotoxic side-effects. The advertised
technology involves substitutions in gene sequences that code for T
cell receptors. Specifically, when TCRs that recognize 1G4 XY-ESO-1
and MART-1 are modified with one- to two amino acid substitutions,
a marked increase in tumor cell recognition occurs. As a platform
technology, the generation of modified TCR directed against a
variety of antigens could enhance the function of gene-modified T
cells. The mutated sequences are currently being evaluated as
candidates for clinical development.
Further R&D
Required:
Potential application for Clinical
Trial
Potential Application
Areas:
- Improved ability of modified TCRs to recognize tumor cell
targets.
- Mutant high affinity TR can also be used to transduce T cells
in order to generate cells reactive with tumor and viral
antigens.
Current State of
Development:
High affinity TCRs are being
evaluated for use in clinical trials to be carried out in the
Surgery Branch, NCI
Patent Status and Relevant
Publications:
- U.S. Provisional Application filed Sept. 2006
- Manuscript in preparation
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #457 EL
Updated 10/24/2007
This opportunity is also listed under the following categories: